Skip to main content

Advertisement

SpringerLink
Log in

How far is the horizon? From current targets to future drugs in advanced renal cancer

  • Invited Review
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

The proliferative control of renal cell cancer (RCC) via vascular endothelial growth factor and mammalian target of rapamycin inhibition by targeted agents has substantially improved survival rates for RCC patients with metastatic (m) disease. However, the management of mRCC remains challenging because some patients are primarily refractory to the approved targeted agents and most therapies eventually fail because of the development of an intractable drug resistance. Tumor progression is closely related to a persistent or restored proliferation via direct and indirect oncogenic signals. Although the elucidation of cancer cell proliferation in the “–omics era” has revealed an enormous number of new potential targets, a comprehensive overview of the different pathways that might serve as new drug targets has become increasingly complex.

Methods/Results

This review highlights the well-trodden pathways in mRCC that are inhibited by targeting agents and describes innovative modes of action within these pathways that are currently not targeted but are under exploration in clinical studies. Additionally, this paper highlights as future drug targets the components of tumor metabolism that supply the tumor cells with nutrition.

Conclusions

These fundamental insights into RCC proliferation as a key driver of progression are urgently needed to overcome the currently improved but still limited targeted drug success.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kruck S, Hennenlotter J, Vogel U, Schilling D, Gakis G, Hevler J, Kuehs U, Stenzl A, Schwentner C (2012) Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications. BJU Int 109(4):634–638. doi:10.1111/j.1464-410X.2011.10392.x

    Article  PubMed  Google Scholar 

  2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013

    Article  CAS  PubMed  Google Scholar 

  3. Kruck S, Bedke J, Kuczyk MA, Merseburger AS (2012) Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 12(6):777–785. doi:10.1586/era.12.43

    Article  CAS  PubMed  Google Scholar 

  4. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE (2009) Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 15(24):7582–7592. doi:10.1158/1078-0432.ccr-09-2131

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. McCarty G, Awad O, Loeb DM (2011) WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J Biol Chem 286(51):43634–43643. doi:10.1074/jbc.M111.310128

    Article  CAS  PubMed  Google Scholar 

  6. Sitaram RT, Degerman S, Ljungberg B, Andersson E, Oji Y, Sugiyama H, Roos G, Li A (2010) Wilms’ tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer 103(8):1255–1262. doi:10.1038/sj.bjc.6605878

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Merseburger AS, Hennenlotter J, Kuehs U, Simon P, Kruck S, Koch E, Stenzl A, Kuczyk MA (2008) Activation of PI3 K is associated with reduced survival in renal cell carcinoma. Urol Int 80(4):372–377. doi:10.1159/000132694

    Article  CAS  PubMed  Google Scholar 

  8. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307–310. doi:10.1038/35042675

    Article  CAS  PubMed  Google Scholar 

  9. Noon AP, Vlatkovic N, Polanski R, Maguire M, Shawki H, Parsons K, Boyd MT (2010) p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer 116(4):780–790. doi:10.1002/cncr.24841

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Kruck S, Merseburger AS, Hennenlotter J, Scharpf M, Eyrich C, Amend B, Sievert KD, Stenzl A, Bedke J (2012) High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int 109(10):1565–1570. doi:10.1111/j.1464-410X.2011.10649.x

    Article  PubMed  Google Scholar 

  11. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732. doi:10.1038/nrc1187

    Article  CAS  PubMed  Google Scholar 

  12. Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22(24):4991–5004. doi:10.1200/jco.2004.05.061

    Article  CAS  PubMed  Google Scholar 

  13. Smaldone MC, Maranchie JK (2009) Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol Oncol 27(3):238–245. doi:10.1016/j.urolonc.2007.12.001

    Article  CAS  PubMed  Google Scholar 

  14. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676. doi:10.1038/nm0603-669

    Article  CAS  PubMed  Google Scholar 

  15. Baldewijns MM, van Vlodrop IJH, Vermeulen PB, Soetekouw PMMB, van Engeland M, de Bruïne AP (2010) VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221(2):125–138. doi:10.1002/path.2689

    Article  CAS  PubMed  Google Scholar 

  16. Zha X, Wang F, Wang Y, He S, Jing Y, Wu X, Zhang H (2011) Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res 71(1):13–18. doi:10.1158/0008-5472.can-10-1668

    Article  CAS  PubMed  Google Scholar 

  17. Godinot C, de Laplanche E, Hervouet E, Simonnet H (2007) Actuality of Warburg’s views in our understanding of renal cancer metabolism. J Bioenerg Biomembr 39(3):235–241. doi:10.1007/s10863-007-9088-8

    Article  CAS  PubMed  Google Scholar 

  18. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M (1994) Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54(15):4233–4237

    CAS  PubMed  Google Scholar 

  19. Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development (Cambridge, England) 125(9):1591–1598

    CAS  Google Scholar 

  20. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18(2):338–340. doi:10.1096/fj.03-0271fje

    CAS  PubMed  Google Scholar 

  21. Currie MJ, Gunningham SP, Turner K, Han C, Scott PAE, Robinson BA, Chong W, Harris AL, Fox SB (2002) Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol 198(4):502–510. doi:10.1002/path.1228

    Article  CAS  PubMed  Google Scholar 

  22. Guertin DA, Sabatini DM (2007) Defining the Role of mTOR in cancer. Cancer Cell 12(1):9–22

    Article  CAS  PubMed  Google Scholar 

  23. Kruck S, Bedke J, Hennenlotter J, Ohneseit PA, Kuehs U, Senger E, Sievert KD, Stenzl A (2010) Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Oncol Rep 23(1):159–163

    CAS  PubMed  Google Scholar 

  24. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126(5):955–968. doi:10.1016/j.cell.2006.06.055

    Article  CAS  PubMed  Google Scholar 

  25. Janssens N, Janicot M, Perera T (2006) The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest New Drugs 24(4):263–280. doi:10.1007/s10637-005-5199-4

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Hamanaka RB, Chandel NS (2012) Targeting glucose metabolism for cancer therapy. J Exp Med 209(2):211–215. doi:10.1084/jem.20120162

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Warburg O (1956) On respiratory impairment in cancer cells. Science (New York, NY) 124(3215):269–270

    CAS  Google Scholar 

  28. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033. doi:10.1126/science.1160809

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M, Saunders RE, Kelly G, Dykema K, Rioux-Leclercq N, Stamp G, Patard JJ, Larkin J, Howell M, Swanton C (2012) Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol 227(2):146–156. doi:10.1002/path.4006

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Parks SK, Chiche J, Pouyssegur J (2011) pH control mechanisms of tumor survival and growth. J Cell Physiol 226(2):299–308. doi:10.1002/jcp.22400

    Article  CAS  PubMed  Google Scholar 

  31. Bedke J, Gouttefangeas C, Kruck S, Stenzl A (2012) A vaccine in renal cell carcinoma: are we nearing reality? Expert Rev Anticancer Ther 12(12):1503–1505. doi:10.1586/era.12.139

    Article  CAS  PubMed  Google Scholar 

  32. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867. doi:10.1038/nature01322

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55(4):851–863. doi:10.1016/j.eururo.2009.01.003

    Article  CAS  PubMed  Google Scholar 

  34. Bedke J, Chun FK, Merseburger A, Scharpf M, Kasprzyk K, Schilling D, Sievert KD, Stenzl A, Kruck S (2012) Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int. doi:10.1111/j.1464-410X.2012.11642.x

    Google Scholar 

  35. Huang D, Ding Y, Li Y, Luo W-M, Zhang Z-F, Snider J, VandenBeldt K, Qian C-N, Teh BT (2010) Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70(3):1053–1062. doi:10.1158/0008-5472.can-09-3722

    Article  CAS  PubMed  Google Scholar 

  36. Motzer RJ (2012) Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma: results of the COMPARZ Trial. ESMO 2012

  37. Motzer RJ, Eisen T, Hutson TE, Szczylik C, Krygowski M, Strahs AL, Esteves B, Krivoshik AP, Berkenblit A, Nosov D (2013) Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma. ASCO Meet Abstr 31(6_suppl):350

    Google Scholar 

  38. http://clinicaltrials.gov/show/NCT00566995

  39. Angevin E, Grunwald V, Ravaud A, Castellano DE, Lin CC, Gschwend JE, Harzstark AL, Chang J, Wang Y, Shi MM, Escudier BJ (2011) A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). ASCO Meet Abstr 29(15_suppl):4551

    Google Scholar 

  40. http://clinicaltrials.gov/show/NCT01223027

  41. Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B (2012) AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 118(24):6152–6161. doi:10.1002/cncr.27632

    Article  CAS  PubMed  Google Scholar 

  42. http://clinicaltrials.gov/show/NCT00467025

  43. http://clinicaltrials.gov/show/NCT01664182

  44. http://clinicaltrials.gov/show/NCT00982657

  45. Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn DI (2012) Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 13(10):1055–1062. doi:10.1016/s1470-2045(12)70364-9

    Article  CAS  PubMed  Google Scholar 

  46. http://clinicaltrials.gov/show/NCT01727336

  47. Karar J, Cerniglia GJ, Lindsten T, Koumenis C, Maity A (2012) Dual PI3 K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1alpha expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther 13(11):1102–1111. doi:10.4161/cbt.21144

    Article  CAS  PubMed  Google Scholar 

  48. Toschi A, Lee E, Gadir N, Ohh M, Foster DA (2008) Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 283(50):34495–34499. doi:10.1074/jbc.C800170200

    Article  CAS  PubMed  Google Scholar 

  49. Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O (2011) Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol cancer 10:90. doi:10.1186/1476-4598-10-90

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. http://clinicaltrials.gov/show/NCT01453595

  51. http://clinicaltrials.gov/show/NCT01442090

  52. Cho DC, Figlin RA, Flaherty KT, Michaelson D, Sosman JA, Ghebremichael M, Bowers ME, Mier JW, Atkins MB, McDermott DF (2009) A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). ASCO Meet Abstr 27(15S):5101

    Google Scholar 

  53. http://clinicaltrials.gov/show/NCT01283048

  54. http://clinicaltrials.gov/show/NCT01239342

  55. Lehmann S, Bykov VJN, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson P-O (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30(29):3633–3639. doi:10.1200/jco.2011.40.7783

    Article  CAS  PubMed  Google Scholar 

  56. Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG (2011) Targeting glucose metabolism: an emerging concept for anticancer therapy. Am J Clin Oncol 34(6):628–635. doi:10.1097/COC.0b013e3181e84dec

    Article  CAS  PubMed  Google Scholar 

  57. http://clinicaltrials.gov/show/NCT00741403

  58. http://clinicaltrials.gov/show/NCT01791595

  59. McDonald PC, Winum JY, Supuran CT, Dedhar S (2012) Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3(1):84–97

    PubMed  Google Scholar 

  60. Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, Hofmann R, Kindler M, Kloepfer P, Stief C (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29(1):121–126. doi:10.1007/s00345-010-0570-2

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler Strasse 3, 72076, Tuebingen, Germany

    Stephan Kruck, Arnulf Stenzl & Jens Bedke

  2. Department of Urology and Urologic Oncology, Medical School of Hanover, Hanover, Germany

    Axel S. Merseburger

Authors
  1. Stephan Kruck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel S. Merseburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arnulf Stenzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jens Bedke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan Kruck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kruck, S., Merseburger, A.S., Stenzl, A. et al. How far is the horizon? From current targets to future drugs in advanced renal cancer. World J Urol 32, 69–77 (2014). https://doi.org/10.1007/s00345-013-1096-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-013-1096-1

Keywords

Search

Navigation